RASL12

Summary

RASL12 (RAS like family 12, HGNC:30289) is a protein-coding gene on chromosome 15q22.31, encoding Ras-like protein family member 12 (Q9NYN1).

Predicted to enable GDP binding activity; GTP binding activity; and GTPase activity. Predicted to be active in plasma membrane.

Source: NCBI Gene 51285 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 133 total — 1 likely-pathogenic
• MANE Select transcript: NM_016563

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30289
Approved symbol	RASL12
Name	RAS like family 12
Location	15q22.31
Locus type	gene with protein product
Status	Approved
Aliases	RIS
Ensembl gene	ENSG00000103710
Ensembl biotype	protein_coding
Entrez	51285

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000220062, ENST00000421977, ENST00000434605

RefSeq mRNA: 3 — MANE Select: NM_016563 NM_001307930, NM_001379429, NM_016563

CCDS: CCDS10200, CCDS76769, CCDS92017

Canonical transcript exons

ENST00000220062 — 5 exons

Exon	Start	End
ENSE00000693607	65058427	65058617
ENSE00000693610	65059345	65059418
ENSE00000693613	65065217	65065273
ENSE00001883781	65053337	65055274
ENSE00001937611	65067733	65067991

Expression profiles

Bgee: expression breadth ubiquitous, 247 present calls, max score 98.79.

FANTOM5 (CAGE): breadth broad, TPM avg 2.3414 / max 99.0472, expressed in 379 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
150518	1.5616	342
150520	0.5110	158
150519	0.1370	77
150517	0.1319	83

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
popliteal artery	UBERON:0002250	98.79	gold quality
tibial artery	UBERON:0007610	98.79	gold quality
saphenous vein	UBERON:0007318	98.52	gold quality
right coronary artery	UBERON:0001625	98.31	gold quality
aorta	UBERON:0000947	97.96	gold quality
thoracic aorta	UBERON:0001515	96.97	gold quality
ascending aorta	UBERON:0001496	96.94	gold quality
descending thoracic aorta	UBERON:0002345	96.76	gold quality
left coronary artery	UBERON:0001626	96.61	gold quality
coronary artery	UBERON:0001621	96.60	gold quality
lower esophagus muscularis layer	UBERON:0035833	96.42	gold quality
lower esophagus	UBERON:0013473	96.36	gold quality
left uterine tube	UBERON:0001303	95.46	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	95.21	gold quality
urethra	UBERON:0000057	95.14	gold quality
body of uterus	UBERON:0009853	94.08	gold quality
right atrium auricular region	UBERON:0006631	93.67	gold quality
mucosa of stomach	UBERON:0001199	93.48	gold quality
cardiac atrium	UBERON:0002081	93.07	gold quality
blood vessel layer	UBERON:0004797	92.89	gold quality
nipple	UBERON:0002030	92.10	gold quality
endocervix	UBERON:0000458	91.22	gold quality
vena cava	UBERON:0004087	90.72	gold quality
upper lobe of left lung	UBERON:0008952	90.43	gold quality
myometrium	UBERON:0001296	90.20	gold quality
upper lobe of lung	UBERON:0008948	90.13	gold quality
prostate gland	UBERON:0002367	89.86	gold quality
muscle layer of sigmoid colon	UBERON:0035805	89.58	gold quality
hypothalamus	UBERON:0001898	89.37	gold quality
seminal vesicle	UBERON:0000998	89.32	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.80

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TSC22D3

miRNA regulators (miRDB)

79 targeting RASL12, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-454-3P	99.91	74.01	1925
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-130A-3P	99.90	73.31	1861
HSA-MIR-130B-3P	99.90	73.27	1850
HSA-MIR-301A-3P	99.90	73.15	1839
HSA-MIR-301B-3P	99.90	73.19	1836
HSA-MIR-3666	99.90	73.24	1833
HSA-MIR-4295	99.90	73.11	1838
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-519D-3P	99.88	73.97	2607
HSA-MIR-526B-3P	99.88	74.06	2587

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	rasl12	ENSDARG00000002701
mus_musculus	Rasl12	ENSMUSG00000041696
rattus_norvegicus	Rasl12	ENSRNOG00000032339

Paralogs (35): RALA (ENSG00000006451), REM1 (ENSG00000088320), RASL10A (ENSG00000100276), RASD2 (ENSG00000100302), RHEB (ENSG00000106615), RASD1 (ENSG00000108551), RERGL (ENSG00000111404), RAP1A (ENSG00000116473), RASL11A (ENSG00000122035), RAP2C (ENSG00000123728), RAP2A (ENSG00000125249), RRAS (ENSG00000126458), RAP1B (ENSG00000127314), RASL11B (ENSG00000128045), KRAS (ENSG00000133703), RRAS2 (ENSG00000133818), RERG (ENSG00000134533), REM2 (ENSG00000139890), RIT1 (ENSG00000143622), RALB (ENSG00000144118), RIT2 (ENSG00000152214), MRAS (ENSG00000158186), DIRAS3 (ENSG00000162595), GEM (ENSG00000164949), DIRAS2 (ENSG00000165023), RRAD (ENSG00000166592), RHEBL1 (ENSG00000167550), NKIRAS2 (ENSG00000168256), HRAS (ENSG00000174775), DIRAS1 (ENSG00000176490), RAP2B (ENSG00000181467), ERAS (ENSG00000187682), NKIRAS1 (ENSG00000197885), NRAS (ENSG00000213281), RASL10B (ENSG00000270885)

Protein

Protein identifiers

Ras-like protein family member 12 — Q9NYN1 (reviewed: Q9NYN1)

Alternative names: Ras-like protein Ris

All UniProt accessions (1): Q9NYN1

UniProt curated annotations — full annotation on UniProt →

Similarity. Belongs to the small GTPase superfamily. Ras family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9NYN1-1	1	yes
Q9NYN1-2	2
Q9NYN1-3	3

RefSeq proteins (3): NP_001294859, NP_001366358, NP_057647* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001806	Small_GTPase	Family
IPR005225	Small_GTP-bd	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR051065	Ras-related_GTPase	Family

Pfam: PF00071

Catalyzed reactions (Rhea), 1 shown:

• GTP + H2O = GDP + phosphate + H(+) (RHEA:19669)

UniProt features (19 total): strand 7, helix 6, binding site 3, splice variant 2, chain 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
3C5C	X-RAY DIFFRACTION	1.85

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NYN1-F1	79.03	0.60

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 27–34; 74–78; 134–137

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 100 (showing top): TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, DORN_ADENOVIRUS_INFECTION_12HR_UP, LFA1_Q6, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP, AP4_Q6, CHANDRAN_METASTASIS_DN, CAGCTG_AP4_Q5, PAPASPYRIDONOS_UNSTABLE_ATEROSCLEROTIC_PLAQUE_DN, INAMURA_LUNG_CANCER_SCC_DN, DORN_ADENOVIRUS_INFECTION_32HR_UP, BLALOCK_ALZHEIMERS_DISEASE_UP, ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, ROSS_AML_WITH_PML_RARA_FUSION

GO Biological Process (0):

GO Molecular Function (7): GTPase activity (GO:0003924), G protein activity (GO:0003925), GTP binding (GO:0005525), GDP binding (GO:0019003), nucleotide binding (GO:0000166), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (1): plasma membrane (GO:0005886)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
guanyl ribonucleotide binding	2
ribonucleoside triphosphate phosphatase activity	1
GTPase activity	1
molecular function regulator activity	1
purine ribonucleoside triphosphate binding	1
anion binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
catalytic activity	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1563 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RASL12	RASL10A	Q92737	494
RASL12	ARL5A	Q9Y689	475
RASL12	RASL10B	Q96S79	427
RASL12	CHRNA7	P36544	404
RASL12	OR52D1	Q9H346	371
RASL12	PFDN1	O60925	368
RASL12	ZNF853	P0CG23	355
RASL12	BRD10	Q5HYC2	348
RASL12	SLC26A1	Q9H2B4	333
RASL12	INTS14	Q96SY0	329
RASL12	TMC5	Q6UXY8	311
RASL12	RASSF7	Q02833	307
RASL12	RASGRP3	Q8IV61	306
RASL12	RHOH	Q15669	304
RASL12	KCNH8	Q96L42	297

IntAct

10 interactions, top by confidence:

A	B	Type	Score
RASL12	FHL2	psi-mi:“MI:0914”(association)	0.740
FHL2	RASL12	psi-mi:“MI:0915”(physical association)	0.740
FHL3	RASL12	psi-mi:“MI:0915”(physical association)	0.560
RASL12	RAP1GDS1	psi-mi:“MI:0914”(association)	0.350
RASL12	FHL3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (14): ARHGEF17 (Affinity Capture-MS), FHL2 (Affinity Capture-MS), RASL12 (Biochemical Activity), ARHGEF17 (Affinity Capture-MS), FHL2 (Affinity Capture-MS), FHL2 (Two-hybrid), FHL3 (Two-hybrid), RASL12 (Affinity Capture-MS), RASL12 (Affinity Capture-MS), RASL12 (Affinity Capture-MS), RAP1GDS1 (Affinity Capture-MS), FHL2 (Affinity Capture-MS), ARHGEF17 (Affinity Capture-MS), APP (Reconstituted Complex)

ESM2 similar proteins: A2YEQ6, O35963, O74536, O95661, O95755, P25378, P35283, P35284, P51156, P52198, P97950, Q00246, Q02723, Q06AU4, Q08AT1, Q08E00, Q09178, Q14088, Q20365, Q29RR0, Q3SXC5, Q3UHC2, Q504M8, Q53S08, Q5H913, Q5JT25, Q5R615, Q5U1Y1, Q5ZHV1, Q62120, Q62689, Q64008, Q69XM7, Q6IQ22, Q75R65, Q7SZ59, Q7TN89, Q7Z444, Q8C0V7, Q8CAM5

Diamond homologs: A1DZY4, A6QP66, A8NU18, C4YKT4, O08989, O14807, O35929, O88667, O93856, O94363, P01119, P03967, P08645, P08647, P0CY32, P10114, P10536, P11233, P11234, P15064, P17609, P22124, P22126, P22278, P22279, P22280, P28775, P32254, P36860, P36863, P48555, P59279, P61105, P61225, P61226, P61227, P62070, P62071, P63320, P63321

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

133 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	98
Likely benign	30
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
804474	NM_178859.4(SLC51B):c.84del (p.Arg29fs)	Likely pathogenic

SpliceAI

847 predictions. Top by Δscore:

Variant	Effect	Δscore
15:65058422:CTCA:C	donor_loss	1.0000
15:65058424:CACC:C	donor_loss	1.0000
15:65058426:C:CG	donor_loss	1.0000
15:65058567:C:CT	acceptor_gain	1.0000
15:65058640:C:T	acceptor_gain	1.0000
15:65067728:CTCA:C	donor_loss	1.0000
15:65067729:TCACC:T	donor_loss	1.0000
15:65067730:CA:C	donor_loss	1.0000
15:65067732:CCAGA:C	donor_gain	1.0000
15:65055270:CTTGC:C	acceptor_gain	0.9900
15:65058425:A:AC	donor_gain	0.9900
15:65058426:C:CC	donor_gain	0.9900
15:65058640:C:CT	acceptor_gain	0.9900
15:65058643:C:CT	acceptor_gain	0.9900
15:65058644:G:T	acceptor_gain	0.9900
15:65059417:CT:C	acceptor_gain	0.9900
15:65059419:C:CC	acceptor_gain	0.9900
15:65065274:C:CC	acceptor_gain	0.9900
15:65067727:ACTCA:A	donor_loss	0.9900
15:65067731:A:AC	donor_gain	0.9900
15:65067732:C:CC	donor_gain	0.9900
15:65055989:C:CT	donor_gain	0.9800
15:65058426:CCT:C	donor_gain	0.9800
15:65058568:A:T	acceptor_gain	0.9800
15:65058613:GTGTC:G	acceptor_gain	0.9800
15:65058616:TC:T	acceptor_gain	0.9800
15:65058617:CC:C	acceptor_gain	0.9800
15:65065211:TCTTA:T	donor_loss	0.9800
15:65065212:CTT:C	donor_loss	0.9800
15:65065213:TTACC:T	donor_loss	0.9800

AlphaMissense

1734 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:65065242:A:C	F45L	1.000
15:65065242:A:T	F45L	1.000
15:65065244:A:G	F45L	1.000
15:65054911:G:C	F263L	0.999
15:65054911:G:T	F263L	0.999
15:65054913:A:G	F263L	0.999
15:65058447:C:A	K135N	0.999
15:65058447:C:G	K135N	0.999
15:65058449:T:C	K135E	0.999
15:65059359:C:G	D74H	0.999
15:65059364:A:T	V72D	0.999
15:65065232:A:G	Y49H	0.999
15:65065243:A:G	F45S	0.999
15:65065255:A:G	L41P	0.999
15:65065258:A:G	F40S	0.999
15:65065270:A:G	L36P	0.999
15:65067735:G:A	S34F	0.999
15:65054906:A:G	I265T	0.998
15:65055173:A:G	F176S	0.998
15:65055206:G:T	A165D	0.998
15:65055209:G:A	S164F	0.998
15:65055255:C:G	G149R	0.998
15:65055269:A:T	V144D	0.998
15:65058450:G:C	N134K	0.998
15:65058450:G:T	N134K	0.998
15:65058454:C:T	G133D	0.998
15:65058537:G:C	S105R	0.998
15:65058537:G:T	S105R	0.998
15:65058539:T:G	S105R	0.998
15:65058560:A:C	Y98D	0.998

dbSNP variants (sampled 300 via entrez): RS1000048869 (15:65075077 A>G,T), RS1000120204 (15:65052333 T>G), RS1000219308 (15:65058637 C>A,T), RS1000416831 (15:65068420 C>T), RS1000438711 (15:65070663 G>A,C), RS1000456371 (15:65052288 C>T), RS1000489089 (15:65070310 T>C), RS1000552319 (15:65051904 C>T), RS1000651112 (15:65075998 T>C), RS1000652350 (15:65064875 T>A,C), RS1000781291 (15:65047514 G>A), RS1000801240 (15:65057999 C>T), RS1001021711 (15:65075813 C>T), RS1001065943 (15:65058212 T>C), RS1001072383 (15:65053915 T>A,C)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:619481

GenCC curated gene-disease

Mondo (2): cholestasis (MONDO:0001751), bile acid malabsorption, primary, 2 (MONDO:0859180)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST011947_36	White matter hyperintensity volume	3.000000e-08
GCST011950_42	White matter hyperintensity volume (adjusted for hypertension)	3.000000e-07
GCST011953_21	White matter hyperintensity volume x hypertension interaction (2df)	2.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0005665	white matter hyperintensity measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D002779	Cholestasis	C06.130.120.135

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	7
trichostatin A	affects cotreatment, increases expression	3
Benzo(a)pyrene	increases methylation, affects methylation, decreases expression	3
entinostat	increases expression, affects cotreatment	2
Vorinostat	increases expression, affects cotreatment	2
aristolochic acid I	increases expression	1
methylmercuric chloride	increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Decitabine	affects expression	1
Ethanol	increases expression	1
Carbamazepine	affects expression	1
Cisplatin	affects expression	1
Diazinon	decreases methylation	1
Diethylhexyl Phthalate	decreases expression	1
Doxorubicin	affects expression	1
Estradiol	affects cotreatment, decreases expression	1
Nickel	decreases expression	1
Progesterone	affects cotreatment, decreases expression	1
Tetrachlorodibenzodioxin	affects expression	1
Dronabinol	decreases expression	1
Thiram	increases expression	1
Triclosan	decreases expression	1
Urethane	decreases expression	1
Tungsten Compounds	decreases expression	1
Antirheumatic Agents	increases expression	1

Clinical trials (associated diseases)

67 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01373918	PHASE4	TERMINATED	Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders
NCT01585935	PHASE4	COMPLETED	Preventing Cholestasis Using SMOFLipid®
NCT01998620	PHASE4	UNKNOWN	Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis
NCT00007020	PHASE3	COMPLETED	Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid
NCT00058890	PHASE3	COMPLETED	Gabapentin to Treat Itch in Patients With Liver Disease
NCT01194063	PHASE3	COMPLETED	Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children
NCT02357576	PHASE3	COMPLETED	Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD
NCT02663453	PHASE3	COMPLETED	Effectiveness of Multicomponent Lipid Emulsion in Preterm Infants Requiring Parenteral Nutrition
NCT03662282	PHASE3	COMPLETED	Omegaven as Alternative Parenteral Fat Nutrition
NCT04167358	PHASE3	ACTIVE_NOT_RECRUITING	Linerixibat Long-term Safety, and Tolerability Study
NCT04309773	PHASE3	UNKNOWN	Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy
NCT00004315	PHASE2	UNKNOWN	Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease
NCT00080236	PHASE2	COMPLETED	Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation
NCT00816348	PHASE2	TERMINATED	Compassionate Use of Omegaven IV Fat Emulsion
NCT00826020	PHASE2	COMPLETED	Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis
NCT00969332	PHASE2	TERMINATED	A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease
NCT01739517	PHASE2	UNKNOWN	Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease
NCT02420496	PHASE2	WITHDRAWN	Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo for the Treatment of Cholestasis in Infants
NCT02966834	PHASE2	COMPLETED	Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis
NCT03586674	PHASE2	COMPLETED	Fibrates in Pediatric Cholestasis
NCT04604652	PHASE2	COMPLETED	Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
NCT00512629	PHASE1	COMPLETED	Cholestasis Prevention: Efficacy of IV Fish Oil
NCT01879735	PHASE1	COMPLETED	Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT
NCT02267707	PHASE1	TERMINATED	Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia
NCT02801981	PHASE1	COMPLETED	Dose-escalation Study of GSK2330672 in Japanese Healthy Male Volunteers
NCT03992014	PHASE1	COMPLETED	Pharmacokinetics (PKs) and Metabolism of Radiolabelled Linerixibat
NCT04053023	PHASE1	COMPLETED	Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects
NCT04510090	PHASE1	COMPLETED	Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
NCT00846963	PHASE2/PHASE3	COMPLETED	Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates
NCT01247012	PHASE2/PHASE3	UNKNOWN	Minimization of IntraLipid Versus Omegaven
NCT02370251	PHASE2/PHASE3	COMPLETED	Compassionate Use of Omegaven in Children
NCT02721277	PHASE1/PHASE2	TERMINATED	SMOFlipid to Lessen the Severity of Neonatal Cholestasis
NCT00004410	Not specified	COMPLETED	Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in Infants
NCT00004414	Not specified	COMPLETED	Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis
NCT00007033	Not specified	COMPLETED	Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease
NCT00135044	Not specified	UNKNOWN	A Trial of Taurine Supplementation in Parenteral Nutrition 1
NCT00392730	Not specified	COMPLETED	Neurodevelopment and Neuroimaging in Parenterally-fed Infants and Young Children
NCT00392977	Not specified	COMPLETED	Brain Manganese Deposition in High Risk Neonates
NCT00685386	Not specified	COMPLETED	A Randomized Controlled Trial (RCT) of Carbon Dioxide Versus Air Insufflation During Endoscopic Retrograde Cholangiopancreatography (ERCP)
NCT00738101	Not specified	COMPLETED	Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants